Pain, PostoperativePhase 3LUMBESNCT03825198
Lumbar Erector Spinae Plane Block for Back Surgery
A Phase 3 study testing Erector spinae plane block, Levobupivacaine 0,25% and spine fusion in people with Pain, Postoperative and Anaesthesia, run by Dr M. B. Breebaart at 2 sites in Belgium.
Trial summary
Title: A prospective randomized double blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24 h morphine consumption after posterior lumbar interbody fusion surgery. Objectives: The primary objective is to study the influence of a bilateral erector spinae block on 24h morphine consumption. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pain, Postoperative, Anaesthesia, Surgery
- What is being tested?
- Erector spinae plane block, Levobupivacaine 0,25% and spine fusion
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 2 sitesBelgium
- Study dates
- 1 Aug 2019to 15 Dec 2023
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- - Patients scheduled for 1-2 level posterior lumbar interfusion surgery in AZ KLINA Hospital or University of Antwerp Hospital (UZA) after approval of Ethical Committee until all required patients are included
- American Society of Anesthesiologist (ASA) score of 1 - 3
- Age 18 - 75 year
- Normal liver and renal function
Who cannot join
- Age <18 years or mentally incompetent
- BMI < 16 or BMI > 35
- Allergy to one or more substances of the study medication (= levobupivacaine, dexamethasone, propofol, sufentanil, rocuronium, ketorolac, morphine, ketamine, DHBP, ondansetron, alizapride)
- Chronic strong opioid use (>3 intakes per week)
Trial locations and contacts
2 sites in 1 country.
Belgium2 sites, 2 recruiting
- Recruiting
University Hospital Antwerp
Antwerp, 2650
Margaretha Breebaart, MD, PhD, 003238213042, margaretha.breebaart@uza.be
Olivier Defre, MD, 003238213042
- Recruiting
AZ KLina
Brasschaat, Antwerp
David van Aken, MD, 0032-3-6505110, David.Van.Aken@klina.be
About this study
Official title: A Prospective Randomized Double Blind Trial of the Efficacy of a Bilateral Lumbar Erector Spinae Block on the 24h Morphine Consumption After Posterior Lumbar Interbody Fusion Surgery.
Title:
A prospective randomized double blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24 h morphine consumption after posterior lumbar interbody fusion surgery.
Read more
Objectives:
The primary objective is to study the influence of a bilateral erector spinae block on 24h morphine consumption.
Endpoint:
The primary endpoint is the 24 h morphine consumption in mg. Secondary endpoints are intraoperative sufentanil requirement, total morphine during first 72 postoperative hours, NRS pain scores in rest and defined movement (moving to chair) at regular time intervals and Quality of Recovery 40 score (QoR-40) at fixed time intervals day 1 and 3 postoperatively
Population:
Patients undergoing posterior lumbar interbody fusion ranging 1 - 3 levels Phase 3
Number of sites Enrolling participants:
University Hospital Antwerp \&AZ KLINA Brasschaat
Description of study agent:
Bilateral erector spinae block: each block contains 20 ml levobupivacaine 0.25% + 5 mcg/ml epinephrine Study duration Until the required study population is met Participant duration 72 hours
Read the detailed description
In this prospective randomized double blind placebo controlled clinical trial we would like to assess the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar interbody fusion surgery. Patients scheduled for 1-2 level PLIF surgery will be recruited in AZ KLINA in Brasschaat and the University Hospital Antwerp in Edegem. The study contains two arms. Subjects will be randomly allocated to an erector spinae block group or the sham block group (placebo).
Stratified randomization will be done according to gender, levels of surgery and site online with Q minim.The study medication will be prepared in identical premade syringes and numbered according to a computer generated block randomization list (1:1 ratio ESB:sham). Subjects will be assigned consecutive numbers upon inclusion to the study and receive the study medication from the corresponding numbered syringes. The study medication in syringes for injection will be prepared by an anesthesiologist neither involved in the study nor in the care of the patient, before handing it over to the investigators. The ESB-group will receive 20 ml Chirocaine 0,25%. The sham block group medication will receive 20 ml Nacl0,9%. The levobupivacaine and saline 0.9% are identical in appearance. All investigators, staff and patients will be blinded to the treatment groups. Epinephrine is added to the placebo block in order to prevent unblinding by increased heart rate or blood pressure. Unmasking will not occur until statistical analysis is complete.
Patients in the erector spinae block group will receive a bilateral ESB block with an injectate containing 20 ml of levobupivacaine 0.25% in each puncture. Patients allocated to the sham group receive a bilateral ESB block with each injectate containing 20 mL of NaCl 0.9% . The blocks will be performed by experts in the field of ultrasound guided locoregional anaesthesia namely dr D. van Aken, dr L. Sermeus and dr M.B. Breebaart who are also teachers for the BARA (Belgian Association of Regional Anaesthesia). The blocks will be performed preoperatively in a separate block room with ultrasound after placement of an iv line and application of standard monitoring (ECG, NIBP, saturation). The blocks will be placed as described by Chin et al. modified for lumbar level.8 First, the patient will be placed in the lateral or sitting position. A curve array probe or a high frequency linear probe, depending on the BMI of the patient, will be placed in a longitudinal position 2-3 cm lateral of the vertebral column. The transverse processes of the vertebrae at the (mid) level of surgery, the erector spinae muscle and the psoas muscle are identified. In case of two level surgery the transverse process of the upper level will be considered as the preferred target. Depending on the depth a 5 or 8 cm 22 G ultrasound needle (Pajunk) will be inserted with an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20 ml of the study medication will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
General anesthesia will then be induced in a standardized way with propofol 2-3mg/kg, sufentanil 15mcg and rocuronium 0.5mg/kg. After tracheal intubation anesthesia will be maintained with sevoflurane and intraoperative analgesia with sufentanil. The dosages of these agents will be determined at the discretion of the anesthesiologist. At the end of surgery patients will receive acetaminophen 1g IV, ketorolac (Taradyl, CSP Benelux) 0.5 mg/kg (max. 30 mg) IV and a morphine loading dose (0.1 mg/kg) IV to manage postoperative pain. Patients will be extubated in the operating theatre and admitted to the post anesthesia care unit (PACU). Postoperative pain in the PACU and on the ward will be treated with acetaminophen 1g IV round the clock (4 times daily) and by a patient controlled intravenous analgesia pump (PCIA) with morphine at a concentration of 1 mg/ml and dehydrobenzperidol (DHBP) 0.05 mg/ml. The PCIA will be set using a standardised protocol: no background administration of morphine, a bolus dose of 1.5 mL morphine with a lock-out interval of 8 minutes and an hourly limit of 7.5 mg. If pain management on the PACU is inadequate (NRS > 3) additional boli of 1 mg morphine IV will be administered with the total additional dose of morphine limited to 0.15mg/kg morphine. In case NRS is still > 3 an IV ketamine (Ketalar, Pfizer) bolus (0.2 mg/kg) will be given. All patients receive dexamethasone 5mg IV as postoperative nausea and vomiting (PONV) prophylaxis. If needed, this will be supplemented by ondansetron 4mg IV and if still insufficient with alizapride 50mg IV. Other study endpoints will be retrieved from the patient data management systems
The morphine consumption during the first 24 hours postoperatively will be extracted out of the PCIA pump. The total morphine dose requirement during the first 72 postoperative hours will also be extracted out of the PCIA pump. Pain scores at rest will be assessed with the numeric rating scale (NRS, 0=no pain 10= worst imaginable pain) and tested at regular time intervals: at the time of inclusion, at the PACU (T0 = arrival at Post Anesthesia Care Unit, T+15min, T+30min) and ward (twice daily- morning and evening until postoperative day 3) Pain scores during defined movement (first moving to chair and upright sitting) will be examined. Time to first mobilization in chair (in hours since T0) and time to first walk of twenty meters (in hours since T0) will be noted in the patients study diary. The quality of recovery 40 score (QoR-40) will be calculated out of a series of questions patients are required to answer at day 1 and 3 postoperatively. The QoR-40 is a widely used and extensively validated measure of quality of recovery. It is a 40-item questionnaire on quality of recovery from anesthesia, that has been shown to measure health status after surgery.
- Conditions
- Pain, Postoperative, Anaesthesia, Surgery, Nerve Block, Anesthesia, Local, Back Pain
- Being tested
- Erector spinae plane block, Levobupivacaine 0,25%, spine fusion, NaCL 0,9%, Sufentanil
- Medical subject headings
- Pain, Postoperative, Back Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Erector spinae plane blockProcedure or surgery
Also called Locoregional anaesthesia
Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
Levobupivacaine 0,25%Drug
Also called chirocaine
20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
spine fusionProcedure or surgery
fusion of lumbar vertebral body on 1 or two levels
NaCL 0,9%Drug
20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
SufentanilDrug
Also called sufenta
opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
propofolDrug
induction agent for general anaesthesia ( 2-3 mg/kg)
Rocuronium BromideDrug
Also called sermon
muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
sevofluraneDrug
inhalation aesthetic used for the maintenance of general anaesthesia
paracetamolDrug
postoperative drug for analgesia ( 1 gram 4/day)
KetorolacDrug
non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
morphine pcaDrug
Also called patient controlled analgesia
postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
DexamethasoneDrug
Also called aacidexam
drug given during general anaesthesia to prevent postoperative nausea
MorphineDrug
loading dose morhine 0,1 mg/kg at the end of surgery
| Study group | Role | What they receive |
|---|---|---|
| ESB group | Active comparator | Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.
Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea. Receives: Procedure: Erector spinae plane block; Drug: Levobupivacaine 0,25%; Procedure: spine fusion; Drug: Sufentanil; Drug: propofol; Drug: Rocuronium Bromide; Drug: sevoflurane; Drug: paracetamol; Drug: Ketorolac; Drug: morphine pca; Drug: Dexamethasone; Drug: Morphine |
| SHAM group | Sham comparator | Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea. Receives: Procedure: Erector spinae plane block; Procedure: spine fusion; Drug: NaCL 0,9%; Drug: Sufentanil; Drug: propofol; Drug: Rocuronium Bromide; Drug: sevoflurane; Drug: paracetamol; Drug: Ketorolac; Drug: morphine pca; Drug: Dexamethasone; Drug: Morphine |
What is being measured
The primary outcome is the main question the study is designed to answer.
24 hour morphine consumption
total milligrams (0-150) of morphine used in the first 24 hours after surgery, extracted out of the pca pump data.
Measured: 24 hours
Secondary outcomes (6)
Intraoperative sufentanyl requirement (
total Intravenous administered sufentanyl in micrograms during surgery(10-100)
Measured: 2-5 hours
Morphine consumption 72 hours
total milligrams of morphine used in 72 hours after surgery (0-450), extracted out of the pca pump data
Measured: 72 hours
NRS pain scores
Numeric rating scale pain score (in numbers) and rest (0= no pain10 =worst thinkable pain)
Measured: at regular intervals and defined movement until 72 hours after surgery
Quality of recovery score (QoR-40)
score in numbers of mental and psychological well being scored by list of questions (minimal score 20-maximum score 200). A high score indicates a better/faster recovery, and is inversely correlated with hospital stay
Measured: day 1 and day 3 postoperatively
time to mobilisation to chair
movements (mobilisation to chair) in hours after surgery
Measured: 8-72 hours
time to 20 meter walking
movement 20 meter walking in hours after surgery
Measured: 8-72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2019
- Study start1 Aug 2019
- Primary completion15 Dec 2023 (estimated)
- Study completion15 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pain, PostoperativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- double blind randomised
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dr M. B. Breebaart
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr M. B. Breebaart, University Hospital, Antwerp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03825198
- Sponsor's protocol ID
- B300201837508
- Acronym
- LUMBES
- Status last verified
- Aug 2022
- First submitted
- 13 Nov 2018
- Last updated
- 5 Aug 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Breebaart MB, Van Aken D, De Fre O, Sermeus L, Kamerling N, de Jong L, Michielsen J, Roelant E, Saldien V, Versyck B. A prospective randomized double-blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar inter-body fusion surgery. Trials. 2019 Jul 17;20(1):441. doi: 10.1186/s13063-019-3541-y.
PubMed 31315670
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Randomized Double Blind Trial of the Efficacy of a Bilateral Lumbar Erector Spinae Block on the 24h Morphine Consumption After Posterior Lumbar Interbody Fusion Surgery.
- ClinicalTrials.gov ID
- NCT03825198
- Acronym / sponsor ID
- LUMBES / B300201837508
- Conditions
- Pain, Postoperative, Anaesthesia, Surgery, Nerve Block, Anesthesia, Local, Back Pain
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Dr M. B. BreebaartUniversity, hospital or other
- Study start
- 1 Aug 2019 (actual)
- Primary completion
- 15 Dec 2023 (estimated)
- Study completion
- 15 Dec 2023 (estimated)
- First posted
- 31 Jan 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Title:
A prospective randomized double blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24 h morphine consumption after posterior lumbar interbody fusion surgery.
Objectives:
The primary objective is to study the influence of a bilateral erector spinae block on 24h morphine consumption.
Endpoint:
The primary endpoint is the 24 h morphine consumption in mg. Secondary endpoints are intraoperative sufentanil requirement, total morphine during first 72 postoperative hours, NRS pain scores in rest and defined movement (moving to chair) at regular time intervals and Quality of Recovery 40 score (QoR-40) at fixed time intervals day 1 and 3 postoperatively
Population:
Patients undergoing posterior lumbar interbody fusion ranging 1 - 3 levels Phase 3
Number of sites Enrolling participants:
University Hospital Antwerp \&AZ KLINA Brasschaat
Description of study agent:
Bilateral erector spinae block: each block contains 20 ml levobupivacaine 0.25% + 5 mcg/ml epinephrine Study duration Until the required study population is met Participant duration 72 hours
Detailed description
In this prospective randomized double blind placebo controlled clinical trial we would like to assess the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar interbody fusion surgery. Patients scheduled for 1-2 level PLIF surgery will be recruited in AZ KLINA in Brasschaat and the University Hospital Antwerp in Edegem. The study contains two arms. Subjects will be randomly allocated to an erector spinae block group or the sham block group (placebo).
Stratified randomization will be done according to gender, levels of surgery and site online with Q minim.The study medication will be prepared in identical premade syringes and numbered according to a computer generated block randomization list (1:1 ratio ESB:sham). Subjects will be assigned consecutive numbers upon inclusion to the study and receive the study medication from the corresponding numbered syringes. The study medication in syringes for injection will be prepared by an anesthesiologist neither involved in the study nor in the care of the patient, before handing it over to the investigators. The ESB-group will receive 20 ml Chirocaine 0,25%. The sham block group medication will receive 20 ml Nacl0,9%. The levobupivacaine and saline 0.9% are identical in appearance. All investigators, staff and patients will be blinded to the treatment groups. Epinephrine is added to the placebo block in order to prevent unblinding by increased heart rate or blood pressure. Unmasking will not occur until statistical analysis is complete.
Patients in the erector spinae block group will receive a bilateral ESB block with an injectate containing 20 ml of levobupivacaine 0.25% in each puncture. Patients allocated to the sham group receive a bilateral ESB block with each injectate containing 20 mL of NaCl 0.9% . The blocks will be performed by experts in the field of ultrasound guided locoregional anaesthesia namely dr D. van Aken, dr L. Sermeus and dr M.B. Breebaart who are also teachers for the BARA (Belgian Association of Regional Anaesthesia). The blocks will be performed preoperatively in a separate block room with ultrasound after placement of an iv line and application of standard monitoring (ECG, NIBP, saturation). The blocks will be placed as described by Chin et al. modified for lumbar level.8 First, the patient will be placed in the lateral or sitting position. A curve array probe or a high frequency linear probe, depending on the BMI of the patient, will be placed in a longitudinal position 2-3 cm lateral of the vertebral column. The transverse processes of the vertebrae at the (mid) level of surgery, the erector spinae muscle and the psoas muscle are identified. In case of two level surgery the transverse process of the upper level will be considered as the preferred target. Depending on the depth a 5 or 8 cm 22 G ultrasound needle (Pajunk) will be inserted with an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20 ml of the study medication will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
General anesthesia will then be induced in a standardized way with propofol 2-3mg/kg, sufentanil 15mcg and rocuronium 0.5mg/kg. After tracheal intubation anesthesia will be maintained with sevoflurane and intraoperative analgesia with sufentanil. The dosages of these agents will be determined at the discretion of the anesthesiologist. At the end of surgery patients will receive acetaminophen 1g IV, ketorolac (Taradyl, CSP Benelux) 0.5 mg/kg (max. 30 mg) IV and a morphine loading dose (0.1 mg/kg) IV to manage postoperative pain. Patients will be extubated in the operating theatre and admitted to the post anesthesia care unit (PACU). Postoperative pain in the PACU and on the ward will be treated with acetaminophen 1g IV round the clock (4 times daily) and by a patient controlled intravenous analgesia pump (PCIA) with morphine at a concentration of 1 mg/ml and dehydrobenzperidol (DHBP) 0.05 mg/ml. The PCIA will be set using a standardised protocol: no background administration of morphine, a bolus dose of 1.5 mL morphine with a lock-out interval of 8 minutes and an hourly limit of 7.5 mg. If pain management on the PACU is inadequate (NRS > 3) additional boli of 1 mg morphine IV will be administered with the total additional dose of morphine limited to 0.15mg/kg morphine. In case NRS is still > 3 an IV ketamine (Ketalar, Pfizer) bolus (0.2 mg/kg) will be given. All patients receive dexamethasone 5mg IV as postoperative nausea and vomiting (PONV) prophylaxis. If needed, this will be supplemented by ondansetron 4mg IV and if still insufficient with alizapride 50mg IV. Other study endpoints will be retrieved from the patient data management systems
The morphine consumption during the first 24 hours postoperatively will be extracted out of the PCIA pump. The total morphine dose requirement during the first 72 postoperative hours will also be extracted out of the PCIA pump. Pain scores at rest will be assessed with the numeric rating scale (NRS, 0=no pain 10= worst imaginable pain) and tested at regular time intervals: at the time of inclusion, at the PACU (T0 = arrival at Post Anesthesia Care Unit, T+15min, T+30min) and ward (twice daily- morning and evening until postoperative day 3) Pain scores during defined movement (first moving to chair and upright sitting) will be examined. Time to first mobilization in chair (in hours since T0) and time to first walk of twenty meters (in hours since T0) will be noted in the patients study diary. The quality of recovery 40 score (QoR-40) will be calculated out of a series of questions patients are required to answer at day 1 and 3 postoperatively. The QoR-40 is a widely used and extensively validated measure of quality of recovery. It is a 40-item questionnaire on quality of recovery from anesthesia, that has been shown to measure health status after surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- double blind randomised
| Arm | Type | Receives |
|---|---|---|
| ESB group | Active comparator | Procedure: Erector spinae plane block, Drug: Levobupivacaine 0,25%, Procedure: spine fusion, Drug: Sufentanil, Drug: propofol, Drug: Rocuronium Bromide, Drug: sevoflurane, Drug: paracetamol, Drug: Ketorolac, Drug: morphine pca, Drug: Dexamethasone, Drug: MorphineErector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane. Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea. |
| SHAM group | Sham comparator | Procedure: Erector spinae plane block, Procedure: spine fusion, Drug: NaCL 0,9%, Drug: Sufentanil, Drug: propofol, Drug: Rocuronium Bromide, Drug: sevoflurane, Drug: paracetamol, Drug: Ketorolac, Drug: morphine pca, Drug: Dexamethasone, Drug: MorphineErector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- - Patients scheduled for 1-2 level posterior lumbar interfusion surgery in AZ KLINA Hospital or University of Antwerp Hospital (UZA) after approval of Ethical Committee until all required patients are included
- American Society of Anesthesiologist (ASA) score of 1 - 3
- Age 18 - 75 year
- Normal liver and renal function
Key exclusion criteria (4 listed)
- Age <18 years or mentally incompetent
- BMI < 16 or BMI > 35
- Allergy to one or more substances of the study medication (= levobupivacaine, dexamethasone, propofol, sufentanil, rocuronium, ketorolac, morphine, ketamine, DHBP, ondansetron, alizapride)
- Chronic strong opioid use (>3 intakes per week)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Erector spinae plane blockAlso: Locoregional anaesthesiaUltrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle | Procedure or surgery | ESB group, SHAM group |
| Levobupivacaine 0,25%Also: chirocaine20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle | Drug | ESB group |
| spine fusionfusion of lumbar vertebral body on 1 or two levels | Procedure or surgery | ESB group, SHAM group |
| NaCL 0,9%20 ml solution used for the infiltration between the transverse process and th erector spinal muscle | Drug | SHAM group |
| SufentanilAlso: sufentaopioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag) | Drug | ESB group, SHAM group |
| propofolinduction agent for general anaesthesia ( 2-3 mg/kg) | Drug | ESB group, SHAM group |
| Rocuronium BromideAlso: sermonmuscle relaxant used during general anaesthesia ( 0,5 mg/kg) | Drug | ESB group, SHAM group |
| sevofluraneinhalation aesthetic used for the maintenance of general anaesthesia | Drug | ESB group, SHAM group |
| paracetamolpostoperative drug for analgesia ( 1 gram 4/day) | Drug | ESB group, SHAM group |
| Ketorolacnon steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg) | Drug | ESB group, SHAM group |
| morphine pcaAlso: patient controlled analgesiapostoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml | Drug | ESB group, SHAM group |
| DexamethasoneAlso: aacidexamdrug given during general anaesthesia to prevent postoperative nausea | Drug | ESB group, SHAM group |
| Morphineloading dose morhine 0,1 mg/kg at the end of surgery | Drug | ESB group, SHAM group |
Primary outcome
24 hour morphine consumption
Time frame: 24 hours
total milligrams (0-150) of morphine used in the first 24 hours after surgery, extracted out of the pca pump data.
6 secondary outcomes
Intraoperative sufentanyl requirement (
Time frame: 2-5 hours
Morphine consumption 72 hours
Time frame: 72 hours
NRS pain scores
Time frame: at regular intervals and defined movement until 72 hours after surgery
Quality of recovery score (QoR-40)
Time frame: day 1 and day 3 postoperatively
time to mobilisation to chair
Time frame: 8-72 hours
time to 20 meter walking
Time frame: 8-72 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2022.
- Derived from this study: PubMed 31315670Breebaart MB, Van Aken D, De Fre O, Sermeus L, Kamerling N, de Jong L, Michielsen J, Roelant E, Saldien V, Versyck B. A prospective randomized double-blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar inter-body fusion surgery. Trials. 2019 Jul 17;20(1):441. doi: 10.1186/s13063-019-3541-y.
- Individual participant dataSharing planned: No
Related trials for Pain, Postoperative
RecruitingPhase 4
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Laparoscopic Surgery, Visceral Pain, Postoperative
Recruiting
NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia
Intraoperative Analgesia
Recruiting
Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery
Postoperative Pain, Facial Swelling
Recruiting
Effect of Ultrasonic and Diode Laser Activated Irrigation on Postoperative Pain Following Root Canal Treatment
Symptomatic Irreversible Pulpitis and Symptomatic Apical Periodontitis
Not yet recruiting
Opioid Reduction and Enhanced Recovery in Orthopaedic Surgery (OREOS)-Knee
Knee Arthroplasty, Total, Partial Knee Arthroplasty
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Erector spinae plane block, Levobupivacaine 0,25% and spine fusion in people with Pain, Postoperative and Anaesthesia, run by Dr M. B. Breebaart at 2 sites in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact margaretha breebaart, MD PhD (003238213865, margaretha.breebaart@uza.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
24 hour morphine consumption (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03825198, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2022.